Treatment of Intracerebral Hemorrhage in Patients on Non-vitamin K Antagonist
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Novel, non-vitamin K antagonist oral anticoagulants (NOAC) target selected players in the
coagulation cascade as the direct thrombin inhibitor dabigatran and the factor Xa-inhibitors
apixaban and rivaroxaban. Intracerebral hemorrhage (ICH) is the most feared complication of
NOAC treatment (NOAC-ICH).
Outcome of NOAC-ICH can be devastating and is a major cause of death and disability. There is
no proven treatment for NOAC-ICH. Hematoma expansion (HE) is associated with unfavorable
outcome. Tranexamic acid (TA) is an anti-fibrinolytic drug that is used in a number of
bleeding conditions other than ICH.